Trial on The Efficacy of Hypertonic Saline on Non-CF CSLD.

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD. Secondary Aims: To determine the: Efficacy of nebulized 5% hypertonic saline on airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics. Efficacy of nebulized 5% hypertonic saline on lung function Adverse effects of nebulized 5% hypertonic saline in children

Detailed Description
-----------------
Primary Aim: To determine the efficacy of nebulized 5% hypertonic saline on cough severity and quality of life, in children with non-CF CSLD. Here the investigators will be using validated pediatric cough questionnaires to asses this. Patients will answer these questionnaires at first recruitment ( -1 mth), at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) Secondary Aims: To determine the: Efficacy of nebulized 5% hypertonic saline on the airway microbiome, pulmonary exacerbation rate, healthcare utilization, and rescue antibiotics. Here the investigators will be taking history on the exacerbations, use of antibiotics and healthcare utilization before and after use of the hypertonic saline. Furthermore, Nasopharyngeal swabs will be done to review possible changes in microbiota, again before and after use of the 5% HS. Efficacy of nebulized 5% hypertonic saline on lung function. Here is investigators will be doing portable spirometry ( pre and post bronchodilator). Patients will perform at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) Adverse effects of nebulized 5% hypertonic saline in children HS has been associated with side-effects. The investigators will monitor this. We will asses presence of these symptoms at randomization (0 month) and after 3 mths of use of the nebulized study drug (+ 3 mths) to ensure these are from the nebulizer.

Official Title
-----------------
Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease

Conditions
-----------------
Bronchiectasis

Intervention / Treatment
-----------------
* Drug: Nebulized 5% Hypertonic saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients < 18 years old Followed up in the paediatric respiratory clinic of UMMC with a diagnosis of CSLD Exclusion Criteria: Incomplete data or refusal to participate Unwell and/or unable to stop HS and/or antibiotics of any preparation other than azithromycin ( EOD On supplementary oxygen/home ventilation Poorly controlled asthma (as in the GINA guidelines) or bronchoconstriction that precedes the use of hypertonic saline. Oral antibiotics for less than 4 weeks before randomization for medication. Fall in PEFR > 20% post 5% HS challenge test or a positive HS challenge test in young children, as mentioned below.

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Double-blind Placebo-controlled trial
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 5% Hypertonic saline<br>5% hypertonic saline nebuliser 4 mls twice in a day for 3 months | Drug: Nebulized 5% Hypertonic saline<br>* nebulized 0.9% saline<br>* Other names: Placebo;|
| Placebo Comparator: Placebo<br>0.9% saline nebuliser 4 mls twice in a day for 3 months | Drug: Nebulized 5% Hypertonic saline<br>* nebulized 0.9% saline<br>* Other names: Placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the Short Parent-proxy cough quality of life (PC-QOL) score | Short PCQOL: This is a validated cough quality-of-life(QoL) questionnaire for parents of children with chronic cough, with a translated Malay version. Minimal Important Difference(MID) of 0.9 has been found in the validation study. The answers are on a Likert scale from 1 (every time) to 7( none). A lower score denotes a lower quality of life. The patients will answer either the English or the translated Malay version | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 
| Change in the Chronic Cough-specific QoL(CC-QOL) score | Chronic cough-specific QOL: This is a validated cough QoL questionnaire to be answered by children 7 years till 18 years old with a MID of about 1.1. The answers are in a Likert scale from 1 ( every time) to 7( none). A lower score denotes a lower quality of life. The patients will answer either the English or the translated Malay version | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Airway microbiome | DNA will be extracted from swabs using the Qiagen DNA Isolation Kit in accordance with the manufacturer's instructions. Bacterial profiling utilised the 16S rRNA gene targeting variable regions V3 - V4 will be carried out using Nextseq 2500 platform. Resulting raw fastq data will be processed using Dada2 R package and exported into phyloseq Rprogram for downstream analysis. The Alpha diversity will be measured using the Shannon and Simpson diversity indices while the beta diversity will be accessed using principle coordinate analysis and Permutational multivariate analysis of variance(PERMANOVA). Differentially abundant taxa will be identified by comparing the fold-change different using DESeq2. | At day 1 of randomization, at 3 months of use of study drug | 
| Number of Exacerbations | Defined as having one major and 2 minor OR 2 major criteria irrespective of whether antibiotics are prescribed. Criteria for exacerbation: Major: (1) Wet cough over 72 hours, (2) Severe cough over 72 hours Minor: (1) Change in Sputum colour, (2) Chest pain, (3) SOB, (4) Haemoptysis, (5) + ve Chest signs At -1 month, we will look at the no of exacerbations in the past 1 year. Before the use of the study drug and after 3 months of use of the study drug, we will look at the no of exacerbations in the preceding 1 month and 3 months, respectively. | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 
| Number of Unscheduled Health Care Visits | any unscheduled doctor visits for cough, shortness of breath or any other respiratory associated symptom. This will be for the last 3 months before day 1 of randomization and after 3 months of use of study drug | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 
| No of episodes of rescue antibiotics | Prescription of antibiotics (including nebulized antibiotics) at least for 3 days for respiratory associated symptoms. This will be in the past 3 months, before randomization and during the next 3 months, while on the study drug. | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 
| FEV1 | FEV1 will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEV1 value will be converted into z-score by using GrowingLungs software. | At day 1 of randomization, at 3 months of use of study drug | 
| FVC | FVC will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FVC value will be converted into z-score by using GrowingLungs software. | At day 1 of randomization, at 3 months of use of study drug | 
| FEF 25-75% | FEF 25-75% will be performed in sitting position(both pre and post 4 puffs of MDI Salbutamol) using the portable spirometry, performed in clinic. The best spirometric measure of at least 3 reproducible attempts will be recorded for analysis. Reference values from Morris/Polgar will be used with ethnic corrections. FEF25-75% value will be converted into z-score by using GrowingLungs software. | At day 1 of randomization, at 3 months of use of study drug | 
| PEFR ( pre and post), if possible | The best PEFR measure out of 3 reproducible attempts ( both pre and post 4 puffs of MDI Salbutamol), performed when relatively well and stable, will be recorded for analysis. | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 
| Cough diary | The cough score will be assessed using the Malay version, used in the HOspitalised Pneumonia Extended study, whereby the cough score will be tabulated daily. The cough diary has recordings for both day time cough: score 0 ( no cough) till score 5 ( Cannot perform most usual day-time activity due to severe coughing). The night cough is scored score 0 ( no cough) till score 5 ( distressing cough.). A higher score indicates more severe cough. | at -1 month of randomization, at day 1 of randomization, at 3 months of use of study drug | 
| Number of Adverse events | cough, haemoptysis, sore throat, throat burning, chest tightness, hoarseness of voice. | At day 1 of randomization, at 3 months of use of study drug | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CSLD, Child, Nebuliser, Hypertonic Saline, Outcome, Chronic cough